It further describes the benefits of MIP as a supplemental additive to an anti-hCG vaccine formulation previously tested in humans, both as an adjuvant for the enhanced generation of anti-hCG immune responses, as well as an elicitor of independent innate anti-tumor immunity. Here, MIP is linked to neoplasm.